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Recent findings of gene fusions in carcinomas recapitulate the discovery of chromosomal abnor-
malities in leukemias and sarcomas decades ago. A recurring feature of carcinoma gene fusions, in 
contrast to those in hematopoietic and mesenchymal malignancies, is that they result in aberrant 
cell signaling. This may reflect differences in the differentiation programs of these tissues.Progress in science is often determined 
by the development of new methods. 
Chromosomal banding and painting 
have played a major part in revealing 
the cytogenetic changes that occur in 
human cancer (balanced and nonbal-
anced translocations, deletions, inser-
tions, and inversions). The correct num-
ber of human chromosomes was not 
established until 1956, when tissue cul-
ture techniques allowed the human chro-
mosome complement to be scored cor-
rectly (Tjio and Levan, 1956). Techniques 
that seem commonplace now, such as 
stimulation of cultured lymphocytes with 
phytohemagglutinin (Nowell and Hun-
gerford, 1960b), led to major discover-
ies and the development of more refined 
techniques for chromosome analysis.
The Philadelphia chromosome in 
chronic myelogenous leukemia (CML), 
described by Nowell and Hungerford 
(1960a), was the first example of a 
consistent aberrant autosomal chro-
mosome in a human cancer. A further 
critical development that placed chro-
mosomal aberrations as causative 
elements in tumorigenesis was the 
demonstration that the Philadelphia 
chromosome was a reciprocal chromo-
somal translocation involving chromo-
some 9 and chromosome 22, t(9;22)
(q34;q11) (Rowley, 1973). In the 1980s, 
the breakpoint of the Philadelphia chro-
mosome was cloned to reveal the fusion 
of the BCR and ABL genes (Figure 1A), 
and the resulting fusion protein was 
shown to be oncogenic (Bartram et al., 
1983; de Klein et al., 1982). In 1992, gene 
fusions in solid tumors—thyroid tumors 
and sarcomas (Ewing’s sarcoma and myxoid liposarcoma)—were discovered 
(reviewed in Rabbitts, 1994). There are 
now many characterized recurrent gene 
fusions in human cancers (reviewed in 
Mitelman et al., 2007). Genes involved in 
these fusions, such as MLL, EWS, and 
RET, may have many different fusion 
partners contributing to leukemia, sar-
coma, or carcinoma, respectively (Rab-
bitts, 1994) (Figure 1A). Further, there are 
many oncogenes activated as a conse-
quence of chromosomal translocations 
resulting in a new transcriptional envi-
ronment principally in hematopoietic 
neoplasias where TCR (encoding the T 
cell receptor) or IG (encoding immuno-
globulins) genes are involved (Figure 1B) 
(for example, see Aifantis et al., 2008).
The Balance of Probability Favors 
Gene Fusions
The discovery of gene fusions was an 
outstanding development. In retrospect, 
it should have been expected in view of 
the exon/intron organization of genes 
and the modular structure of proteins, 
which corresponds (at least in part) to 
exon organization. Given the often large 
size of introns, it would be expected on 
a probabilistic basis that breaks within 
genes would occur within introns and 
that fusion genes would be the most 
likely outcome of chromosomal break-
age and rejoining. Furthermore, active 
genes are more likely to be targets as the 
accessibility of chromatin (associated 
with active genes) is a key element in 
facilitating translocations/inversions and 
may even occur by corecruitment to the 
same transcription factories (Osborne et 
al., 2007).CeIt is also predictable that nonrecur-
rent gene fusions will occur in tumors 
by chromosome breakage and rejoining 
within intronic regions (genetic instabil-
ity). Nonrecurrent events may contribute 
to the development and maintenance of 
the individual tumor (idiopathic) (Rab-
bitts, 1994) or have no consequence at 
all. In some cases—as found in mouse 
modeling of chromosomal translocations 
using the Cre-loxP system (Forster et al., 
2003)—it may be that nontumorigenic 
gene fusions occur that create fusions 
with exons in opposite transcriptional 
orientations. These may persist in the 
tumors that appear in patients.
There are parallels between the func-
tion of fusion gene products and the 
roles of the individual proteins in normal 
development (Rabbitts, 1991). For exam-
ple, genes required in differentiation 
pathways (e.g., the mixed lineage leu-
kemia gene, MLL) may also be involved 
in gene fusions in acute neoplasias. The 
MLL protein is frequently found as part 
of a fusion protein in myeloid and lym-
phoid lineage tumors (Rowley, 2000). 
MLL controls both primitive and definitive 
hematopoiesis (Armstrong et al., 2003), 
behaving like a master gene in both nor-
mal and neoplastic settings. This prop-
erty is found in many of the consistently 
fused genes in acute hematopoietic and 
mesenchymal malignancies (the trans-
location master gene hypothesis; Rab-
bitts, 1991).
Gene Fusions in Carcinomas
Although cytogenetic analyses of car-
cinomas (that is, tumors of epithelial 
cell origin) have lagged behind those of ll 137, May 1, 2009 ©2009 Elsevier Inc. 391
hematopoietic malignancies and sarco-
mas, it is now clear that carcinomas also 
have chromosomal abnormalities that 
result in the formation of fusion genes. 
The first example found in epithelial 
tumors, in the early 1990s, was in papil-
lary thyroid carcinoma, the most preva-
lent form of thyroid cancer. This gene 
fusion involves joining of the RET gene 
encoding a tyrosine kinase receptor with 
the CCDC6 gene (previously D10S170); 
there are also nine other fusions involv-
ing the tyrosine kinase domain of RET 
in papillary thyroid carcinoma (Fusco 
et al., 1987; Grieco et al., 1988) (Fig-
ure 1A). In addition, there are five other 
gene fusions, bringing the proportion of 
papillary thyroid carcinomas with gene 
fusions to ?50%. Clearly, abnormal 
tyrosine kinase activity resulting from 
Figure 1. Chromosomal Rearrangements in Cancer
(A–C) Chromosomal abnormalities (translocations, inversions, deletions, insertions) can result in either fu-
sion of an oncogene with another gene (A and C) or forced activation of an oncogene (B) (Rabbitts, 1994). 
Gene fusions happen when breaks occur in introns, causing a new splicing combination that results in 
exon fusions, leading to protein fusion products. Forced expression of oncogenes through rearrange-
ments in immunoglobulin (IG) or T cell receptor (TCR) genes is found in B cell neoplasias (e.g., MYC in 
Burkitt’s lymphoma) and T cell neoplasias (e.g., LMO2 in T cell acute leukemia). Often, the transcriptional 
promoter of the oncogene accompanies the coding exons, causing aberrant expression of the mRNA 
but production of a normal protein. MYC mutations are the exception in translocations involving IG loci in 
Burkitt’s lymphoma (Rabbitts et al., 1983).
(C) Gene fusions in lung and prostate cancer. Chromosomal translocations in lung cancer may involve 
kinase domain-encoding genes such as ALK and ROS (Rikova et al., 2007). In prostate cancer, ETS gene 
family members are fused to androgen-responsive genes or ubiquitous promoters that sometimes con-
tribute noncoding exons to fusions with ETS coding exons.392 Cell 137, May 1, 2009 ©2009 Elsevier Inc.these gene fusions plays a pivotal role in 
the generation and sustenance of these 
epithelial tumors. The promiscuity of RET 
in gene fusions and the specific associa-
tion of papillary thyroid carcinoma with 
a variety of gene fusions foreshadowed 
the discovery of similar fusions involving 
the MLL, EWS, and FUS genes.
Gene Fusions in Breast, Prostate, 
and Lung Cancer
Since the initial findings in thyroid can-
cers, other gene fusions have been dis-
covered in carcinomas (reviewed in Mitel-
man et al., 2007). One example is the 
ETV6-NTRK3 fusion resulting from the 
t(12;15)(p12;q26.1) translocation in secre-
tory breast ductal carcinoma (Tognon et 
al., 2002). Transformation by the fusion 
protein ETV6-NTRK3 works through the 
RAS-MAPK and PI3K-AKT signaling 
pathways and activates the AP1 tran-
scription complex (Li et al., 2007).
Recent studies have identified impor-
tant new gene fusions in prostate and 
lung cancer. In prostate cancer, bio-
informatics approaches assessing gene 
expression have revealed that ETS fam-
ily transcription factor genes form fusion 
products in many prostate tumors. 
Initially, a gene encoding a transmem-
brane serine protease TMPRSS2 (an 
androgen-responsive gene; Tomlins et 
al., 2005) was found to be fused with 
ERG (ETS-Related Gene) by either inver-
sion of chromosome 21 or by intersti-
tial deletion of chromosome 21q22; a 
TMPRSS2-ETV1 gene fusion was found 
to be caused by chromosomal translo-
cation between chromosomes 21 and 7. 
Additional ETS gene fusions have been 
described involving other androgen-
responsive genes or ubiquitous promot-
ers (Kumar-Sinha et al., 2008) (Figure 
1C). The consequence of gene fusions 
in prostate cancer seems to involve one 
of two features: either androgen-respon-
sive and ubiquitously expressed pro-
moters control ETS gene expression, or 
5′ untranslated regions are fused to the 
ETS gene so that the protein product is 
not a chimera (typical of hematopoietic 
or mesenchymal cancers), but rather is 
a deregulated ETS protein. In essence, 
this resembles the forced expression 
of oncogenes often found in lymphoid 
tumors (Figure 1B). After chromosomal 
translocation, expression of genes like 
Figure 2. Different Fusion Genes Reflect Different Tissue Biology
(A) Gut epithelia are replenished by gut epithelial stem cells in the crypts, which first become transit-amplifying cells and then differentiate into postmi-
totic cells.
(B and C) In contrast, hematopoietic and mesenchymal tissues arise from pluripotent stem cells that generate multipotent progenitor cells, which in turn pro-
duce fully differentiated functional cells. Acute cancers of hematopoietic and mesenchymal tissues often have gene fusions encoding proteins that play a role in 
transcription and developmental control (the translocation master gene model; Rabbitts, 1991). Epithelial gene fusions, on the other hand, involve a less diverse 
set of genes, many of which are involved in cell signaling.BCL2 in follicular lymphoma or LMO2 in 
T cell acute leukemia results in a normal 
protein product but with aberrant control 
of transcription.
Recurrent gene fusions resulting in 
quintessential protein fusion products 
have also been found in lung cancer. 
Using a new approach—reminiscent of 
pioneering experiments identifying cel-
lular transforming genes by transfec-
tion of tumor DNA into nontransformed 
fibroblasts (reviewed in Karnoub and 
Weinberg, 2008)—fusion between the 
anaplastic lymphoma kinase gene (ALK) 
and the echinoderm microtubule-asso-
ciated protein-like 4 gene (EML4) has 
been detected in a subset of non-small 
cell lung cancers (NSCLCs) (Soda et al., 
2007) (Figure 1C). The EML4-ALK fusion 
gene is created by an inversion of chro-
mosome 2p and encodes a fusion pro-
tein retaining the kinase domain of ALK. 
Further, ROS kinase (highly expressed in 
NSCLCs) also becomes part of a fusion 
protein in lung tumors, with the trans-
membrane portions of either SLC34A2 
or CD74 (Rikova et al., 2007) creating the chimeric kinase. The importance of 
kinase signaling pathways and mutations 
in lung cancer has been clear from the 
prevalence of overexpressed or mutated 
RAS and PI3K in lung tumor tissue. This 
connection is now solidified with the 
identification of the ALK and ROS fusion 
proteins in lung tumors.
Different Biology, Different Fusion 
Protein Functions
Carcinomas encompass potentially 
invasive cancers that arise from the epi-
thelium, which is the layer of cells lin-
ing cavities and surfaces (e.g., mouth, 
esophagus, lung, gut) or lining the ducts 
of glands (e.g., thyroid, breast, prostate). 
The developmental potential of stem 
cells in epithelial layers differs from that 
of blood or mesenchymal stem cells 
(Figure 2), and so the types of genetic 
abnormality resulting in tumor forma-
tion are also likely to differ. Hematopoi-
etic stem cells and mesenchymal stem 
cells undergo differentiation into diverse 
lineages (Figures 2B and 2C) that have 
distinct transcriptomes. These transcrip-Cetomes deliver the complex differentiation 
programs needed to produce diverse 
types of cell progeny. Conversely, epi-
thelial stem cells undergo fewer differen-
tiation steps and act to directly replenish 
layers of depleted cells at the epithelial 
surface.
In carcinomas, we see a trend toward 
oncogenic proteins that are involved in 
signaling pathways that activate cell 
proliferation or maintain homeostasis. 
Gross chromosomal mutations that 
affect signaling pathways may occur 
more frequently in locations, such as 
the airways, where there is contact with 
environmental agents or carcinogens. 
The gene fusions in lung tumors involving 
kinases (ALK and ROS) exemplify the link 
between the chromosomal abnormality, 
the gene fusion, the protein product, and 
abnormal signaling. The recent findings 
of mutations in the ALK gene in neuro-
endocrine tumors supports this path-
way to tumorigenesis (Chen et al., 2008; 
George et al., 2008; Janoueix-Lerosey et 
al., 2008; Mosse et al., 2008). An appar-
ent exception is the association of gene ll 137, May 1, 2009 ©2009 Elsevier Inc. 393
fusions involving the ETS family of tran-
scription factors with prostate cancer. 
The mechanism and role of inappropri-
ate expression of these fusion proteins in 
prostate cancer has not been fully evalu-
ated as yet. However, expression array 
analysis of prostate tumors carrying ETS 
gene abnormalities suggests that ETS 
proteins are involved in a broad range of 
normal and abnormal cellular processes 
from adhesion to invasion (Tomlins et al., 
2008). Although fusion genes in carcino-
mas point to the importance of aberrant 
signaling cascades in the formation of 
these tumors, kinase involvement is not 
exclusive to carcinomas given that acti-
vated kinases such as BCR-ABL are the 
cause of chronic leukemia.
The Future
Since the Philadelphia chromosome 
was discovered and shown to be a 
reciprocal translocation, the importance 
of chromosomal abnormalities in defin-
ing molecular events that initiate and 
maintain tumors has been established 
for all forms of human cancer. Undoubt-
edly, further consistent reciprocal and 
nonreciprocal translocations, intrachro-
mosomal deletions (possibly also inser-
tions), and inversions (associated with 
DNA replication and repair events such 
as breakage and rejoining), followed 
by clonal selection, will be discovered. 
This will lead to the identification of new 
gene fusions (Rabbitts, 1994). In addi-
tion, gene activation (as seen in lym-
phoid tumors) may also be discovered 
in carcinomas.
Application of new high-throughput 
genome sequencing technologies has 
begun to fulfill the promise of the facile 
and rapid discovery of new gene fusions 
(Campbell et al., 2008; Ley et al., 2008). 
These technologies should reveal, in the 
complex genomes of all human malig-
nancies, new recurrent abnormalities 
and nonrecurrent (idiopathic) oncogenic 
abnormalities that ensure development 
or maintenance of the individual tumor. 
They should also reveal abnormalities 
that have no oncogenic role (Rabbitts, 
1994); these can be considered to be 
passenger abnormalities, akin to the 
passenger somatic mutations discov-
ered by systematic sequencing of cancer 
genomes (Greenman et al., 2007; Wood 
et al., 2007).394 Cell 137, May 1, 2009 ©2009 Elsevier InThe importance of fusion proteins in 
cancer cannot be overstated, both for 
understanding more about the complex 
events underlying cancer and for identi-
fying suitable therapeutic targets. How-
ever, a measure of caution is needed 
with respect to fusion proteins as thera-
peutic targets. Although the fusion pro-
teins are tumor-specific targets, they are 
mostly intracellular molecules that are 
not expressed on the tumor cell surface. 
In addition, many are not enzymes but 
rather are involved in protein-protein or 
protein-nucleic acid interactions, mak-
ing them more challenging drug targets. 
This contrasts with the ABL kinase of 
the BCR-ABL fusion protein, which is 
targeted by the drug Gleevec that binds 
competitively to the ATP-binding site of 
the kinase (Sawyers, 2005).
Many gross chromosomal changes 
should prove valuable for early detec-
tion of cancer, leading to better informed 
clinical decisions. The recent finding 
of trans-spliced fusion mRNAs in nor-
mal endometrial stromal cells identical 
to those found in endometrial stromal 
tumors (Li et al., 2008) is an unexpected 
complication, and we clearly need to 
know more about how fusion mRNAs are 
created through trans-splicing. Molecu-
lar biologists have highlighted a plethora 
of gene fusions and their protein prod-
ucts, and it is now incumbent on us to 
turn these discoveries into new diagnos-
tic and therapeutic regimens for combat-
ing cancer.
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